{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:08:35Z","timestamp":1790485715165,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bulcan.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T05:53:44Z","timestamp":1530165224000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["La toxicit\u00e9 cardiaque des fluoropyrimidines\u00a0: 5-fluorouracile, cap\u00e9citabine, le compos\u00e9 S-1\u00a0et le trifluridine\/tipiracil"],"prefix":"10.1016","volume":"105","author":[{"given":"Pauline","family":"Vaflard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lopez-Trabada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0300","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.005_bib0305","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0315","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"D\u00e9pistage du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u00a0: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0320","series-title":"5-fluorouracile\u00a0: donn\u00e9es sur le m\u00e9tabolisme et place actuelle dans le traitement des cancers digestifs","author":"Aparicio","year":"2008"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0325","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/OTT.S19059","article-title":"Tegafur\/gimeracil\/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies","volume":"4","author":"Kobayakawa","year":"2011","journal-title":"OncoTargets Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0330","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.005_bib0335","first-page":"154","article-title":"Cardiotoxicit\u00e9 du 5-fluoro-uracile","volume":"91","author":"Teixeira","year":"2004","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0340","first-page":"17","article-title":"Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature","author":"Coen","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.005_bib0345","article-title":"Vasospasme coronarien secondaire \u00e0 l\u2019administration de cap\u00e9citabine","volume":"42","author":"Lord","year":"2009","journal-title":"Pharmactuel"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.005_bib0350","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.005_bib0355","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.005_bib0360","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"8740","key":"10.1016\/j.bulcan.2018.05.005_bib0365","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0140-6736(91)91353-V","article-title":"Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche)","volume":"337","author":"Lemaire","year":"1991","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.005_bib0370","first-page":"340","article-title":"Experimental myocarditis; anatomical study of 210\u00a0rat hearts after ingestion of 5-fluorouracil","volume":"166","author":"Levillain","year":"1972","journal-title":"C R Seances Soc Biol Fil"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0375","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1097-0142(19900215)65:4<885::AID-CNCR2820650410>3.0.CO;2-H","article-title":"Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin","volume":"65","author":"Kuzel","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.005_bib0385","first-page":"215","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene","volume":"10","author":"Shahrokni","year":"2009","journal-title":"JOP J Pancreas"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0390","first-page":"531","article-title":"Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series","volume":"27","author":"Saif","year":"2013","journal-title":"Vivo Athens Greece"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2261-1-3","article-title":"5-Fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report","volume":"1","author":"McGlinchey","year":"2001","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"10.1016\/j.bulcan.2018.05.005_bib0400","first-page":"1715","article-title":"Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients","volume":"34","author":"Sakata","year":"1998","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"18","key":"10.1016\/j.bulcan.2018.05.005_bib0405","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2018.05.005_bib0410","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1\u00a0with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"Ajani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10041","key":"10.1016\/j.bulcan.2018.05.005_bib0415","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1\u00a0versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.005_bib0420","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S1470-2045(14)70025-7","article-title":"Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1\u00a0versus UFT or S-1\u00a0monotherapy as adjuvant chemotherapy for T4a\/b gastric cancer (SAMIT): a phase 3\u00a0factorial randomised controlled trial","volume":"15","author":"Tsuburaya","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2018.05.005_bib0425","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/annonc\/mdu232","article-title":"S-1\u00a0as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)","volume":"25","author":"Yoshida","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0430","unstructured":"teysuno__03102012_avis_ct12048.pdf.[Internet, cit\u00e9 15\u00a0janv 2018, disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-10\/teysuno__03102012_avis_ct12048.pdf]."},{"key":"10.1016\/j.bulcan.2018.05.005_bib0435","unstructured":"CT-15304_LONSURF_PIC_INS_Avis3_CT15304.pdf. [Internet, cit\u00e9 8\u00a0mars 2017, disponible sur\u00a0: http:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-15304_LONSURF_PIC_INS_Avis3_CT15304.pdf]."},{"key":"10.1016\/j.bulcan.2018.05.005_bib0440","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00280-016-3031-9","article-title":"Phase 1\u00a0study of cardiac safety of TAS-102\u00a0in patients with advanced solid tumors","volume":"77","author":"Bendell","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.bulcan.2018.05.005_bib0445","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102\u00a0for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0450","article-title":"Results of a randomized, double-blind, placebo-controlled. Phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA Study","author":"Xu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0455","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clcc.2016.04.004","article-title":"TAS-102\u00a0safety in metastatic colorectal cancer: results from the first postmarketing surveillance study","volume":"15","author":"Yoshino","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.bulcan.2018.05.005_bib0460","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2018.36.4_suppl.816","article-title":"Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine\/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"36","author":"Hollebecque","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.005_bib0465","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdt479","article-title":"Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines","volume":"25","author":"Ransom","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0470","unstructured":"tomudex__reeval_liste_en_sus_avis2_ct13562.pdf. [Internet, cit\u00e9 4\u00a0avr 2017, disponible sur\u00a0: http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2014-07\/tomudex__reeval_liste_en_sus_avis2_ct13562.pdf]."},{"issue":"9","key":"10.1016\/j.bulcan.2018.05.005_bib0475","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","article-title":"Final results of a randomised trial comparing \u00ab\u00a0Tomudex\u00a0\u00bb (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. \u201cTomudex\u201d Colorectal Cancer Study Group","volume":"7","author":"Cunningham","year":"1996","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2018.05.005_bib0480","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.005_bib0485","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000094357","article-title":"Randomised trial comparing three different schedules of infusional 5-FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer","volume":"70","author":"Ducreux","year":"2006","journal-title":"Oncol"},{"issue":"9317","key":"10.1016\/j.bulcan.2018.05.005_bib0490","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0495","unstructured":"Haute Autorit\u00e9 de sant\u00e9 - TEYSUNO. [Internet, cit\u00e9 23\u00a0avr 2018, disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_1329540\/en\/teysuno]."},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.005_bib0500","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"issue":"11","key":"10.1016\/j.bulcan.2018.05.005_bib0505","first-page":"1542","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.005_bib0510","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000072334","article-title":"High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102\u00a0patients","volume":"65","author":"Wacker","year":"2003","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0515","first-page":"887","article-title":"Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy: an echocardiographic study","volume":"7","author":"Balloni","year":"2000","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.bulcan.2018.05.005_bib0520","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000227226","article-title":"Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study","volume":"50","author":"Akhtar","year":"1993","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0525","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/1120009X.1990.11739029","article-title":"Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin","volume":"2","author":"Jeremic","year":"1990","journal-title":"J Chemother Florence Italy"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.005_bib0530","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.005_bib0535","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","article-title":"Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil","volume":"13","author":"Eskilsson","year":"1988","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.005_bib0540","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1\u00a0plus cisplatin versus S-1\u00a0alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2018.05.005_bib0545","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102\u00a0monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2\u00a0trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2018.05.005_bib0550","first-page":"46","article-title":"A multicenter phase II study of TAS-102\u00a0monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)","volume":"62","author":"Bando","year":"2016","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.005_bib0555","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/bjc.2012.274","article-title":"Phase I study of TAS-102\u00a0treatment in Japanese patients with advanced solid tumours","volume":"107","author":"Doi","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.005_bib0560","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-015-2850-4","article-title":"Phase 1\u00a0study of oral TAS-102\u00a0in patients with refractory metastatic colorectal cancer","volume":"76","author":"Bendell","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.05.005_bib0565","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/cncr.22125","article-title":"Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102\u00a0in patients with solid tumors","volume":"107","author":"Hong","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.005_bib0570","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10637-008-9142-3","article-title":"Phase 1\u00a0study of TAS-102\u00a0administered once daily on a 5-day-per-week schedule in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Invest New Drugs"},{"issue":"23","key":"10.1016\/j.bulcan.2018.05.005_bib0575","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2018.05.005_bib0580","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.bulcan.2018.05.005_bib0585","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07\u00a0trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.05.005_bib0295","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/annonc\/mdw404","article-title":"Phase III trial comparing 3\u20136\u00a0months of adjuvant FOLFOX4\/XELOX in stage II\u2013III colon cancer: safety and compliance in the TOSCA trial","volume":"27","author":"Lonardi","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T19:53:15Z","timestamp":1720381995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118301711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":59,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0007455118301711"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.05.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La toxicit\u00e9 cardiaque des fluoropyrimidines\u00a0: 5-fluorouracile, cap\u00e9citabine, le compos\u00e9 S-1\u00a0et le trifluridine\/tipiracil","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}